Corvus Pharmaceuticals (CRVS) Retained Earnings (2015 - 2026)

Corvus Pharmaceuticals' Retained Earnings history runs 12 years deep, the most recent figure standing at -$426.0 million for Q1 2026.

• In Q1 2026, Retained Earnings fell 11.57% year-over-year to -$426.0 million; the TTM figure through Mar 2026 stood at -$426.0 million (down 11.57% YoY), while the FY2025 annual figure was -$896000.0, up 30.43% from the prior year.
• Retained Earnings was -$426.0 million for Q1 2026 at Corvus Pharmaceuticals, down from -$896000.0 in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$738000.0 in Q3 2024 to a low of -$426.0 million in Q1 2026.
• Historically, Retained Earnings has averaged -$260.2 million across 5 years, with a median of -$315.6 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Retained Earnings sank 331037.35% in 2022, then soared 99.62% in 2024.
• A 5-year view of Retained Earnings shows it stood at -$307.7 million in 2022, then slipped by 8.78% to -$334.7 million in 2023, then jumped by 99.62% to -$1.3 million in 2024, then jumped by 30.43% to -$896000.0 in 2025, then sank by 47442.97% to -$426.0 million in 2026.
• The last three Retained Earnings figures came in at -$426.0 million (Q1 2026), -$896000.0 (Q4 2025), and -$400.0 million (Q3 2025), per Business Quant data.